Text written in Basque and translated automatically by Elia without any subsequent editing. SEE ORIGINAL

Lenacapabir does not interfere with the treatment of hormonal transas

Previous studies have also suggested that lenacapabir does not interact with hormonal contraceptives and hormone therapy taken by some trans people. The latter has now been confirmed during the week of the American Infectious Diseases Association (IDWeek 2025).

Lenakapabir has this year obtained the authorization to be marketed in Europe under the name Yeytuo, and has also received the approval of the World Health Organization. This is a significant step forward in the prevention of AIDS, as two injections per year are sufficient to prevent HIV infection. Taking into account that the trans group is more vulnerable than the general population, a specific study has been carried out to see if it causes discomfort at the hormonal level in those who undergo hormonal treatment.

“They conclude that there is no interaction and that both treatments can be taken together.”

Thus, the hormone levels of 2,000 people (estradiol, testosterone and a derivative thereof) before and after taking lenacapavir have been measured; 253 of these people were taking hormones. It has been shown that lenacapabir did not cause significant changes in hormone levels. Therefore, it is concluded that there is no interaction and that both treatments (HIV prevention and hormonal) can be co-administered.